查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594657

眼科药品市场：依配药类型、疾病、产品类型、剂型、分布划分 - 全球预测 2025-2030

Ophthalmic Drugs Market by Dispense Type (Over the Counter, Prescription), Disease Condition (Allergy, Dry Eye Disorder, Glaucoma), Products, Dosage Form, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年眼科药品市场价值为289.9亿美元，预计到2024年将达到305.6亿美元，复合年增长率为5.86%，到2030年达到432.1亿美元。

由于360iResearch的市场研究分析师专注于眼科药物，本次研究的范围涵盖了用于治疗多种眼科疾病的药物，包括青光眼、干眼症、视网膜疾病和感染疾病。这些药物有多种形式，包括眼药水、药膏和口服锭剂，旨在解决影响眼睛解剖和功能的疾病。由于人口老化、看萤幕时间增加以及眼睛健康意识增强，眼科疾病盛行率不断上升，推动了对眼科药物的需求。这些药物在医院药房、零售药房和线上管道中至关重要，因为它们的多种用途既可用于治疗又可用于预防。市场成长主要是由药物输送系统的技术进步、对微创治疗的需求不断增长以及主要企业之间扩大产品系列的策略联盟所推动的。

主要市场统计
基准年[2023] 289.9亿美元
预测年份 [2024] 305.6亿美元
预测年份 [2030] 432.1亿美元
复合年增长率（%） 5.86%

最新的机会在于个人化医疗的发展，即利用基因组学根据个别患者的情况量身定制治疗方案，以及缓释性药物输送系统的创新，以提高患者的依从性和疗效。公司可以透过进入医疗保健基础设施不断扩张的亚太地区等新兴市场来发现巨大的成长潜力。然而，严格的监管障碍和先进治疗的高成本可能会造成进入障碍并抑制新药物核准。他们也面临假药影响品牌信誉的挑战。

创新应着重于基因疗法和生技药品的突破，为治疗以前无法治疗的疾病提供新途径。加速探索眼科微生物组与全身性疾病之间关係的研发工作可能会开闢新的治疗前沿。眼科药品市场本质上是动态的，具有缓慢到快速的成长轨迹，并强调透过品质和患者结果实现差异化。了解以患者为中心的需求并相应地优化产品平臺对于确保在不断变化的环境中实现持续的业务成长和竞争优势至关重要。

市场动态：揭示快速发展的眼科药品市场的关键市场洞察

供需的动态交互作用正在改变眼科药品市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 眼科疾病和适应症的兴起
    • 扩大眼科疾病联合治疗的开发
    • 提高认识、获得治疗的机会和药物的供应
  • 市场限制因素
    • 开发成本高，研发时间长
  • 市场机会
    • 供应商增加投资和研发活动以开发新的眼科药物
    • 眼科生技药品的巨大潜力
  • 市场挑战
    • 眼科药物的副作用不受监控

波特五力：驾驭眼科药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解眼科药品市场的外部影响

外部宏观环境因素在塑造眼科药品市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解眼科药品市场竞争状况

眼科药品市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵眼科药物市场供应商的绩效评估

FPNV 定位矩阵是评估眼科药品市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为眼科药物市场的成功指明道路

对于旨在加强其在全球市场的影响力的公司来说，对眼科药品市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球眼科疾病和适应症的盛行率不断上升
      • 眼科治疗联合治疗的发展取得进展

障碍

      • 提高意识、获得治疗的机会和药物的供应
    • 抑制因素
      • 眼科药物的开发成本高、研发耗时。
    • 机会
      • 供应商增加对眼科药品新开发的投资和研发活动
      • 眼科生技药品的巨大潜力
    • 任务
      • 眼科药物的副作用不受监控
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依配药类型分類的眼科药品市场

  • 在商店
  • 处方笺

第七章依疾病区分的眼科药物市场

  • 过敏
  • 干眼症
  • 青光眼
  • 视网膜疾病
    • 糖尿病视网膜病变
    • 干老龄化黄斑部病变
    • 湿性老龄化黄斑部病变

第八章眼科药品市场：副产品

  • 胶囊和片剂
  • 降低
  • 凝胶
  • 软膏
  • 解决方案和暂停

第九章按剂型分類的眼科药物市场

  • 液体眼药水
  • 多室给药系统
  • 半固态眼药水
  • 固态眼药水

第十章 眼科药品市场经销商

  • 药局
  • 医院药房
  • 网路药房

第十一章美洲眼科药品市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区眼科药品市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲眼科药品市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 博士伦计划收购 XIIDRA
    • FDA核准NovaricCyclosporine眼药水用于治疗干眼症
    • Eyenovia 与 Formosa 合作开发新型眼科治疗药物
    • Rivana 融资 1,200 万美元用于开发缓释眼内植入
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Alcon Vision LLC
  • Allergan PLC by AbbVie Inc.
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Carl Zeiss AG
  • Coherus Biosciences, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Eyevensys
  • Genentech, Inc.
  • Johnson & Johnson Service, Inc.
  • Kodiak Sciences Inc.
  • Lupin Limited
  • Merck & Co.
  • Nicox SA
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-036C5CF3A8ED

The Ophthalmic Drugs Market was valued at USD 28.99 billion in 2023, expected to reach USD 30.56 billion in 2024, and is projected to grow at a CAGR of 5.86%, to USD 43.21 billion by 2030.

As a Market Research Analyst focusing on Ophthalmic Drugs at 360iResearch, the scope of the study encompasses drugs used to treat various eye disorders, including glaucoma, dry eye syndrome, retinal disorders, and infections. These drugs come in multiple forms such as eye drops, ointments, and oral tablets aimed at addressing diseases affecting the eye's anatomy and functionality. The necessity for ophthalmic drugs is driven by the rising prevalence of eye conditions due to the aging population, increased screen time, and growing awareness about eye health. Various applications apply to both therapeutic and preventive care, making these drugs crucial across hospital pharmacies, retail pharmacies, and online channels. Market growth is significantly influenced by technological advancements in drug delivery systems, the increasing demand for minimally invasive treatments, and strategic partnerships among key players to expand product portfolios.

KEY MARKET STATISTICS
Base Year [2023] USD 28.99 billion
Estimated Year [2024] USD 30.56 billion
Forecast Year [2030] USD 43.21 billion
CAGR (%) 5.86%

Latest opportunities reside in the development of personalized medicine, which harnesses genomics to tailor treatments specific to individual patient profiles, and innovations in sustained-release drug delivery systems that enhance patient adherence and efficacy. Companies can tap into emerging markets like Asia-Pacific, where expanding healthcare infrastructure presents notable growth potential. However, stringent regulatory hurdles and the high cost of advanced therapies pose barriers to entry and can curtail new drug approvals. The market also faces challenges with counterfeit drugs impacting brand integrity.

Innovation should focus on breakthroughs in gene therapy and biologics that offer new pathways for treating previously untreatable conditions. Accelerated R&D efforts in exploring the ocular microbiome and its correlations with systemic diseases could open new therapeutic frontiers. The ophthalmic drug market exemplifies a dynamic nature, with a moderate to fast-growth trajectory and a strong emphasis on differentiation through quality and patient outcomes. Understanding patient-centric needs and optimizing product pipelines accordingly will be pivotal for sustained business growth and competitive advantage in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ophthalmic Drugs Market

The Ophthalmic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of ophthalmic disorders and indications globally
    • Growing development combination therapies for the treatment of ophthalmic disorders
    • Increased awareness, treatment accessibility and drug availability
  • Market Restraints
    • High development costs and time taking research and development of ophthalmic drugs
  • Market Opportunities
    • Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
    • Significant potential in ophthalmic biologics
  • Market Challenges
    • Unmonitored side effects of ophthalmic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Ophthalmic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ophthalmic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ophthalmic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ophthalmic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ophthalmic Drugs Market

A detailed market share analysis in the Ophthalmic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ophthalmic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ophthalmic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ophthalmic Drugs Market

A strategic analysis of the Ophthalmic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ophthalmic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alcon Vision LLC, Allergan PLC by AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, Coherus Biosciences, Inc., EyePoint Pharmaceuticals, Inc., Eyevensys, Genentech, Inc., Johnson & Johnson Service, Inc., Kodiak Sciences Inc., Lupin Limited, Merck & Co., Nicox SA, Novaliq GmbH, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Recipharm AB, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Ophthalmic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dispense Type, market is studied across Over the Counter and Prescription.
  • Based on Disease Condition, market is studied across Allergy, Dry Eye Disorder, Glaucoma, and Retinal Disorder. The Retinal Disorder is further studied across Diabetic Retinopathy, Dry Age-related Macular Degeneration, and Wet Age-related Macular Degeneration.
  • Based on Products, market is studied across Capsules & Tablets, Drops, Gels, Ointments, and Solutions & Suspensions.
  • Based on Dosage Form, market is studied across Liquid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Semisolid Ophthalmic Drug Forms, and Solid Ophthalmic Drug Forms.
  • Based on Distribution, market is studied across Drug Stores, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of ophthalmic disorders and indications globally
      • 5.1.1.2. Growing development combination therapies for the treatment of ophthalmic

disorders

      • 5.1.1.3. Increased awareness, treatment accessibility and drug availability
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and time taking research and development of ophthalmic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
      • 5.1.3.2. Significant potential in ophthalmic biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Unmonitored side effects of ophthalmic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ophthalmic Drugs Market, by Dispense Type

  • 6.1. Introduction
  • 6.2. Over the Counter
  • 6.3. Prescription

7. Ophthalmic Drugs Market, by Disease Condition

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Dry Eye Disorder
  • 7.4. Glaucoma
  • 7.5. Retinal Disorder
    • 7.5.1. Diabetic Retinopathy
    • 7.5.2. Dry Age-related Macular Degeneration
    • 7.5.3. Wet Age-related Macular Degeneration

8. Ophthalmic Drugs Market, by Products

  • 8.1. Introduction
  • 8.2. Capsules & Tablets
  • 8.3. Drops
  • 8.4. Gels
  • 8.5. Ointments
  • 8.6. Solutions & Suspensions

9. Ophthalmic Drugs Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Liquid Ophthalmic Drug Forms
  • 9.3. Multicompartment Drug Delivery Systems
  • 9.4. Semisolid Ophthalmic Drug Forms
  • 9.5. Solid Ophthalmic Drug Forms

10. Ophthalmic Drugs Market, by Distribution

  • 10.1. Introduction
  • 10.2. Drug Stores
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies

11. Americas Ophthalmic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Ophthalmic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Ophthalmic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bausch + Lomb Plans to Acquire XIIDRA
    • 14.3.2. FDA Approves Novaliq's Cyclosporine Ophthalmic Solution For Treatment Of Dry Eye Disease
    • 14.3.3. Eyenovia and Formosa Partner For New Ophthalmic Therapeutics
    • 14.3.4. Re-Vana Reels in USD 12M To Develop Sustained-Release Eye Implants
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alcon Vision LLC
  • 3. Allergan PLC by AbbVie Inc.
  • 4. Apotex Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Carl Zeiss AG
  • 8. Coherus Biosciences, Inc.
  • 9. EyePoint Pharmaceuticals, Inc.
  • 10. Eyevensys
  • 11. Genentech, Inc.
  • 12. Johnson & Johnson Service, Inc.
  • 13. Kodiak Sciences Inc.
  • 14. Lupin Limited
  • 15. Merck & Co.
  • 16. Nicox SA
  • 17. Novaliq GmbH
  • 18. Novartis AG
  • 19. Ocular Therapeutix, Inc.
  • 20. OCuSOFT Inc.
  • 21. Pfizer Inc.
  • 22. Recipharm AB
  • 23. Regeneron Pharmaceuticals, Inc.
  • 24. Santen Pharmaceutical Co., Ltd.
  • 25. Senju Pharmaceutical Co., Ltd.
  • 26. Somerset Pharma, LLC.
  • 27. Sun Pharmaceutical Industries, Inc.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Teva Pharmaceutical Industries Ltd.
  • 30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OPHTHALMIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPHTHALMIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY EYE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CAPSULES & TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY LIQUID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SEMISOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 284. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023